BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DEMENTIA RESEARCHER - ECPv6.14.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DEMENTIA RESEARCHER
X-ORIGINAL-URL:https://www.dementiaresearcher.nihr.ac.uk
X-WR-CALDESC:Events for DEMENTIA RESEARCHER
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251201
DTEND;VALUE=DATE:20251205
DTSTAMP:20260730T212426
CREATED:20250721T084331Z
LAST-MODIFIED:20250805T100506Z
UID:10001848-1764547200-1764892799@www.dementiaresearcher.nihr.ac.uk
SUMMARY:Clinical Trials on Alzheimer's Disease (CTAD)
DESCRIPTION:The Clinical Trials on Alzheimer’s Disease conference (CTAD) is a meeting focused entirely on Alzheimer’s Disease Therapeutic Trials with key leaders in Alzheimer Disease research from Industry and Academia getting together and forming partnerships with the objective of speeding the development of effective treatments to fight the disease. \nThe 18th annual CTAD conference will be held in San Diego\, CA\, USA on December 1-4\, 2025.  \nLooking forward to seeing you in San Diego in 2025! \nFind out More
URL:https://www.dementiaresearcher.nihr.ac.uk/event/clinical-trials-on-alzheimers-disease-ctad-2/
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2025/07/CTAD-Logo-2025.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251205
DTEND;VALUE=DATE:20251208
DTSTAMP:20260730T212426
CREATED:20250306T202824Z
LAST-MODIFIED:20250310T090143Z
UID:10001691-1764892800-1765151999@www.dementiaresearcher.nihr.ac.uk
SUMMARY:International Symposium on ALS / MND
DESCRIPTION:The International Symposium on ALS/MND is a unique annual event that brings together leading international researchers and health and social care professionals to present and debate key innovations in their respective fields. The Symposium is planned as two parallel meetings\, one on biomedical research and the other on advances in clinical research and treatment of people affected by ALS/MND. Joint sessions consider issues of mutual interest\, challenging current views and practices. \nAbout the Symposium \nThe International Symposium encompasses innovation\, education and collaboration\, as researchers and healthcare professionals come together to update colleagues from across the world on the latest developments in the diagnosis\, treatment and management of ALS/MND. This meeting allows researchers to share the latest information on disease pathology\, clinical practice\, and potential therapeutic targets to a global audience. The Symposium also offers the unique opportunity for researchers to appreciate the reality of the disease from the perspective of the people living with MND\, medical practitioners and caregivers\, to feel part of the whole MND community. \nWhat’s on offer this year? \nThe Symposium Programme Committee\, chaired by Professor Ammar Al-Chalabi\, will consider a broad range of cutting-edge topics for this year’s programme. We will continue to showcase a mix between biomedical research and clinical science\, therapy development and clinical management\, through dedicated oral presentations and poster sessions (which have always been a Symposium highlight). We would encourage as many members of the ALS/MND research and clinical/care communities to join us in-person\, but to remain inclusive to those unable to travel (particularly people living with ALS/MND)\, we are once again offering a virtual option. The virtual option will consist of a selection of live-streamed sessions\, and access to all session recordings post-event (until early March\, 2026). \nWe look forward to welcoming you \nWe hope the Symposium will once again motivate you to make a difference in the work you do for people living with ALS/MND. Last year’s closing session showcased how the latest advancements in technology could help to improve quality of life for people with ALS/MND. The BrainGate Consortium Team was presented with the International Healey Award for Innovation in ALS for their work on Brain Computer Interface (BCI) technology. The development of this technology offers the opportunity to restore communication\, mobility and independence in people living with ALS/MND. This research illustrates hope for the future and the impact research can have on the lives of people with ALS/MND. We hope that this year’s meeting will offer inspiration and the opportunity to stimulate new ideas\, partnerships and collaborations that will lead to further advances in ALS/MND. \nRegistration\nRegistration for in-person attendance will be available from 6 May and registration for those who wish to attend virtually (access the selected live and recorded content only) will be available from 6 September at www.symposium.mndassociation.org/register. A provisional Symposium programme will be available on our website in August. The final programme will be available in November. \nCall for abstracts\nAbstracts must be submitted online\, via a link on the MND Association’s Symposium website (https://www.symposium.mndassociation.org/abstracts). Abstracts cannot be accepted via email. \nAbstracts must be submitted by the presenting author of the abstract\, who must provide an email address to which all Symposium correspondence will be sent. The presenting author is the only person who will receive email correspondence from us. \nSubmissions are limited to two abstracts per presenting author. \nAuthors may submit an abstract for consideration in one of three categories: oral\, poster or work in progress/care practice (WIP/CP) poster presentations. WIP/CP is defined as: preliminary work (little or no data/results)\, care practice or case studies. \nImportant: Authors accepting the offer of an oral or poster presentation must attend the Symposium in-person in San Diego\, USA and be present for their assigned session. \nThe presenting author is not required to fully register for the Symposium before submitting an abstract. However\, formal acceptance of an abstract is conditional upon payment of the appropriate registration fee no later than 5 September 2025. Failure to pay the registration fee by this date will result in withdrawal of the abstract. \nAbstracts must be in English and be no longer than 450 words. The MND Association will not correct any errors\, so authors must ensure their abstract is checked for grammar\, understanding and accuracy. Authors should provide a clear description of methodology and present statistically robust data (including ‘n’ and ‘p’ values) where appropriate. \nAuthors must ensure they have the correct permissions to submit their abstract (e.g. from collaborators and funders). \nThe corresponding oral/poster presentation must discuss the same work as the accepted abstract. \nAbstracts will be published in an open access online supplement to the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. Abstracts accepted as ‘WIP/CP’ will be published on the MND Association’s Symposium website. \nAuthors will also be asked to confirm if the presenting author is eligible and willing to be included in the poster prize competition (see below). The deadline for withdrawing an abstract is 5 September. Abstracts withdrawn after this date will still be published in the journal supplement. \nFull instructions and Conditions of Acceptance will be available on the MND Association’s website before the opening of the submission system on 6 May 2025. These must be read before an abstract is submitted. Queries should be sent to abstracts@ mndassociation.org. \nAbstract submission system opens: 6 May 2025 \nDeadline for abstract submission: 10 July 2025 \nPoster prize\nThe International Symposium on ALS/MND poster prize celebrates early-stage career ALS/MND researchers’ outstanding work\, presented at the conference poster session. \nPrizes will be awarded for the best clinical and best biomedical posters presented at the conference. \nEarly career researchers are eligible to enter if they are aged 35 years or under on the abstract submission deadline date OR if they were awarded their PhD within three years of the abstract submission deadline. \nThe initial stage of judging will be based on the abstracts\, as submitted by the abstract submission deadline of 10 July 2025. Final judging of shortlisted posters will take place at the conference. \nFull terms and conditions for the poster prize will be available on the MND Association’s website (https://www.symposium.mndassociation.org/for-presenters/poster-prize) following the opening of the abstract submission system in May 2025.
URL:https://www.dementiaresearcher.nihr.ac.uk/event/international-symposium-on-als-mnd/
LOCATION:Loews Coronado Bay Resort\, 4000 Coronado Bay Road\, Coronado\, San Diego\, 92118\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2025/03/36th-International-Symposium-on-ALS-MND.png
ORGANIZER;CN="MND Association":MAILTO:fundraising@mndassociation.org
GEO:32.6319231;-117.1343534
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Loews Coronado Bay Resort 4000 Coronado Bay Road Coronado San Diego 92118 United States;X-APPLE-RADIUS=500;X-TITLE=4000 Coronado Bay Road:geo:-117.1343534,32.6319231
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251206
DTEND;VALUE=DATE:20251211
DTSTAMP:20260730T212426
CREATED:20250402T111024Z
LAST-MODIFIED:20250325T121630Z
UID:10001716-1764979200-1765411199@www.dementiaresearcher.nihr.ac.uk
SUMMARY:Cell Bio Conference 2025
DESCRIPTION:The year’s joint meeting of the American Society for Cell Biology (ASCB) and the European Molecular Biology Organization (EMBO) takes place in Philadelphia\, USA\, in early December. Cell Bio 25 offers a varied program which aims to bring together researchers\, educators and innovators for networking\, exploring cutting-edge techniques and sharing the latest discoveries in cell biology. \nThousands of attendees are expected at this popular event\, with the full program yet to be released but expected to include career-building workshops\, keynote speeches\, symposia and much more. \nEarly registration closes on 30th September 2025. \nFind out more: https://www.ascb.org/cellbio2025/
URL:https://www.dementiaresearcher.nihr.ac.uk/event/cell-bio-conference-2025/
LOCATION:Pennsylvania Convention Center\, 1101 Arch Street\, Philadelphia\, PA 19107\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2025/03/Cell-Bio-2025.png
GEO:39.9553197;-75.1600104
X-APPLE-STRUCTURED-LOCATION;VALUE=URI;X-ADDRESS=Pennsylvania Convention Center 1101 Arch Street Philadelphia PA 19107 United States;X-APPLE-RADIUS=500;X-TITLE=1101 Arch Street:geo:-75.1600104,39.9553197
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20251209T090000
DTEND;TZID=Europe/London:20251209T173000
DTSTAMP:20260730T212426
CREATED:20251127T193339Z
LAST-MODIFIED:20251127T193339Z
UID:10002004-1765270800-1765301400@www.dementiaresearcher.nihr.ac.uk
SUMMARY:Proteomics: a new era for Biomarkers in Medicine
DESCRIPTION:Join Alamar Biosciences and Spedali Civili di Brescia\, University of Brescia for an intensive\, one‑day translational forum uniting internationally recognised KOLs to examine what’s ready now in proteomic biomarkers and explore how the sensitivity of the NULISA ™ technology is applied to Biomarkers Discovery and Clinical Development. \nDiscover the latest breakthroughs and innovative approaches using NULISA\, an ultra-high sensitivity proteomic platform measuring proteins down to a level of fg/ml in multiplex format. This cutting-edge technology holds the promise of advancing and transforming our understanding\, as well as finding new treatments for different disease conditions. \n\n09:00 – 09:15 | OPENING SESSION\n\n\n\n\n\n09:00 – 09:15 | Welcome and Opening\, Alessandro Padovani & Andrea Pilotto\, University of Brescia\, ASST Spedli Civili of Brescia\n\n09:15 – 11:30 | SESSION ONE | Biomarker discovery\n\n\n\n\n09:15 – 10:00 | NULISA™ and its use in fluid biomarker discovery\, Michael Evans & Mathias Holpert\, Alamar Biosciences\n10:00 – 10:30 | Proteomic profiling in Multiple Sclerosis\, Jens Kuhle\, Basel Hospital\, Switzerland (Virtual)\n10:30 – 11:00 | Biomarkers discovery across neurodegenerative conditions\, Andrea Benedet\, University of Gothenburg\, Sweden\n11:00 – 11:30 | Coffee Break\n\n11:30 – 13:45 | SESSION TWO | Animal models and new protein targets\n\n\n\n\n11:30 – 12:00 | Mouse models in TBI and Neurodegeneration\, Federico Moro\, Mario Negri Milan\, Italy\n12:00 – 12:30 | Proteomic profiles as new target in ALS\, Alberto Catanese\, University of Freiburg\, Germany (Virtual)\n12:30 – 13:00 | Inflammatory profiles in central and peripheral conditions\, Matteo Gastaldi\, University of Pavia\, Italy\n13:00 – 13:45 | Lunch & Networking\n\n13:45 – 16:00 | SESSION THREE | Brain health beyond\n\n\n\n\n13:45 – 14:10 | Biomarkers of Brain Health in at-risk individuals\, Paula Ortiz-Romero\, BarcelonaBeta Brain Research Center\, Spain\n14:10 – 14:35 | Biomarkers of Brain health in general aging population\, Giulia Grande\, Karolinska Institute\, Sweden\n14:35 – 15:00 | Proteomics profiling in type 2 diabetes and obesity\, Prof. Edoardo Mannucci\, University of Florence\, Italy\n15:00 – 15:30 | Biological and molecular basis of Major Psychiatric disorders: overview and future perspectives\, Prof Antonio Rampino\, University of Bari\, Italy\n15:30 – 16:00 | Coffee Break\n\n16:00 – 16:40 | SESSION FOUR | Key lecture\n\n\n\n\n16:00 – 16:40 | Proteomic biomarkers discovery: challenges\, opportunities and future scenarios\, Nick Ashton\, Bannerhealth\, U.S.A (Virtual)\n\n16:45 – 17:45 | SESSION FIVE | Ongoing projects & Closing\n\n\n\n\n16:45 – 17:30 | Flash communication and ongoing projects\n17:30 – 17:45 | Closing remarks followed by networking reception\n\n\nRegister to Attend
URL:https://www.dementiaresearcher.nihr.ac.uk/event/proteomics-a-new-era-for-biomarkers-in-medicine/
LOCATION:Online\, United Kingdom
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2025/09/Alamar-Biosciences-virtual-ARGOnaut-Club-Voyager-Summit-2025.png
END:VEVENT
END:VCALENDAR